Forward-Looking Statements





Certain statements, other than purely historical information, including
estimates, projections, statements relating to our business plans, objectives,
and expected operating results, and the assumptions upon which those statements
are based, are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934.  These
forward-looking statements generally are identified by the words "believes,"
"project," "expects," "anticipates," "estimates," "intends," "strategy," "plan,"
"may," "will," "would," "will be," "will continue," "will likely result," and
similar expressions. We intend such forward-looking statements to be covered by
the safe-harbor provisions for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995, and are including this
statement for purposes of complying with those safe-harbor
provisions. Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may cause actual
results to differ materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on our operations
and future prospects on a consolidated basis include, but are not limited to:
changes in economic conditions, legislative/regulatory changes, availability of
capital, interest rates, competition, cybersecurity, and generally accepted
accounting principles. These risks and uncertainties should also be considered
in evaluating forward-looking statements and undue reliance should not be placed
on such statements. We undertake no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise. Further, information concerning our business, including
additional factors that could materially affect our financial results, is
included herein and in our other filings with the SEC.



Overview

Global Stem Cell Group Operations

Global Stem Cells Group's operations are dedicated to the regenerative medicine
industry. We work with doctors and their staff to provide products, solutions,
equipment, services, and training to help them be successful in the application
of Stem Cell Therapies. Our team combines solutions from extensive clinical
research with the manufacturing and commercialization of viable cell therapy and
immune support related products that we believe will change the course of
traditional medicine around the world forever. Our strategy allows us the
ability to create immediate revenue streams through product sales, distribution,
and clinical applications, driven by our extensive education platform. Our
revenue comes directly from the training and the seminars, from the resale of
these kits, products, and equipment, services, and from the reoccurring
application of our process using the kits and solutions we provide.



Global Stem Cells Group is a leader in the Stem Cell and Regenerative Medicine
fields, covering clinical research, patient applications, along with physician
training through our state-of-the-art global network of companies. The Company's
mission is to enable physicians to make the benefits of stem cell medicine a
reality for patients around the world. They have been educating doctors on the
science and application of cell-based therapeutics for the past 10 years. Our
professional trademarked association "ISCCA" INTERNATIONAL SOCIETY FOR STEM CELL
APPLICATION is a global network of medical professionals that leverages these
multinational relationships to build best practices and further our mission.

The Company envisions the ability to improve "health-span" through the discovery and developments of new cellular therapy products, and cutting-edge technology.

Global Stem Cells Group, as almost everyone else in the world, was severely affected by the covid 19 pandemic. As we look to recover in 2022, we are integrating every aspect of the regenerative medicine industry. During 2022, we plan to add manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever.

We believe this strategy will allow us the ability to increase our current revenues and create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform here are our main projects and revenue generators for 2022 and beyond.





Manufacturing Facilities

Permanent Treatment Center of Excellence and Physician Training in Istanbul, Turkey





Our Flagship Operation in "Istanbul Center" deploys well-targeted combinations
of Exosomes, allogeneic human Mesenchymal cells, autologous bone marrow, and
Adipose derived stem cells to treat a wide array of diseases and debilitating
medical conditions.



Since 2018, we have completed over 7 industry seminars and training sessions in
Istanbul. Through our joint venture/partnership with Biotrend Technology that
was completed in February this year, our treatment plans are focused mostly on a
systemic and/or whole-body approach. This new processing facility works with our
local partner to provide the latest in Stem Cell Therapies to many of those in
this region who have no access to these kinds of cutting-edge medical solutions.
Our physician training services will help educate and generate demand for our
solutions, services, and products.



                                       26





Biotrend Technology's CEO, Dr Salih Yildrim, is the acting ISSCA Director and
this center operates under our brand Global Stem Cell Group name. Biotrend
Technology is a fully staffed facility that operates also in other forms or
regenerative health procedures that we do not participate in. This Joint Venture
operates as a pure revenue sharing agreement whereas we do not own the lease,
employees, or any other P&L expenses. They operate under the GSCG name,
utilizing our products, services, training, and procedures. Dr. Salih Yildirim
sits on our GSCG staff and is the Director of Overseas Operations. He functions
as the International Relations Program Manager at Cleveland Clinic Turkey and is
GSCG's Managing Director over BioTrend Medical International. He is also engaged
in consulting and identifying business development opportunities locally and
regionally

Cell Therapy Product Manufacturing Facility in Cancun Mexico

The Cancun facility that is to begin operations in July of 2022 has been accredited both by the Mexican General Health Council and Cofepris (Mexican FDA). GSCG's processing operation is in the well-known HELLIMEX, S.A. DE CV building, a high-rise office of leased suites that provide a multitude of other professional services.





We have assembled a highly qualified team of medical professionals and
technicians that specialize in GSCG's processes, solutions, and services. Our
processing facilities in Cancun is top-notch, and include a laboratory to
culture-expand cells, a process that yields better patient results, and a
cryopreservation unit to keep these extracted samples stored safely until they
are needed. This Laboratory/ Treatment Center will have the latest technologies
available including NK Cell Therapy CAR T-cell for cancer treatment and produce
full Lines of Msc and Exosomes. Our model is to work hand-in-hand with the
patients' physicians to provide a total quality experience in this innovative
industry. Our revenue is derived from training doctors, providing services to
each patient that these doctors bring to us for treatments, and the solutions
and products they utilize.

Cell Therapy Product manufacturing facility in Dubai UAE

Similar to Cancun, we are in the process of building out a leased suite and equipping this facility in the well-known healthcare city DUBAI UAE. This facility will serve patients and physicians from the Middle East and Asia and will have the same capabilities as our Cancun counterpart.





Products




Solidifying and increasing our Presence worldwide www.cellgenic.com, we are
completing our new catalog of Cell Therapy products manufactured completely in
house as opposed of our previous re seller model. This new series of products
include:



    ?   CELLGENIC FLOW EXOSOMES This is the company's flagship product, which
        stands ready to revolutionize the practice of regenerative medicine as we
        know it today. Exosomes are extracellular vesicles that float freely
        within the blood, very much like platelets. These are cell-derived

non-particles that play a pivotal role in cell-to-cell communication that

are involved in a wide range of physiological processes. Exosomes play an

important role in the transfer of proteins and other bioactive molecules


        between cells and regulate gene expression in recipient cells, thus
        influencing various molecular pathways and have a wide range of
        therapeutic implications, including hair loss and pain management.




    ?   CELLGENIC MSC (Mesenchymal Stem Cell) This product excretes growth
        factors, cytokines, and proteins, which all play a key role in the

regeneration of tissue. Their anti-inflammatory and immunomodulatory

properties mean that it is difficult for them to be rejected by the body.

Additionally, they increase blood flow to the vital organs that need it


        the most. MSC has immunomodulatory effects that have an effect on
        macrophages, neutrophils, NK cells, mast cells and dendritic cells in
        innate immunity with known anti-inflammatory benefits.

? CELLGENIC LUMA (Lyophilized Exosomes) is derived from human umbilical cord

mesenchymal stem cells and includes potent growth factors, peptides,

coenzymes, minerals, amino acids, vitamins and UV radiation reducing

agents for skin revitalization. Exosomes are extracellular vesicles, which


        is the medical term for tiny bubbles that are released from stem cells.
        Exosomes carry genetic information and proteins to cells throughout your
        body, and they create paths for communication between cells to help combat
        aging skin, environmental damage and loss of elasticity and tone.




                                       27

? VITANOVAS is a mobile IV infusion company that provides in-home treatments


        to patients in need of immune modulation to help fight infections,
        viruses, and diseases.




    ?   GCELL RESTORE GCell technology is a closed-system medical device that

harnesses the natural and powerful restorative capabilities of adipose

tissue. It is a cutting-edge tool that utilizes micrograft technology to

harness the natural and powerful restorative capabilities of adipose

tissues. This is a precise system that is able to process a stem cell

sample from adipose tissue in less than half of the time that it would

take a physician to do so through traditional means. This allows the

patient to be more comfortable throughout the shorter procedure, as less

anesthesia is also required than when operating under traditional means.

The GCell is a minimally invasive, portable machine that allows physicians

to fully unlock the potential of regenerative medicine as a component in


        their practice.

? CELLGENIC SVF is an isolation kit system that has all the ingredients and


        consumables for the extraction of adipose-Derived Stem cells from fat.
        This complete kit it is currently being used in clinical procedures for
        lung disease, intra-articular injections for osteoarthritis of the knee
        and hip, cosmetic surgery, dermal injection, stem cell enriched fat
        transfer, wounds chronic ulcers among other chronic conditions.

? CELLGENIC BONE MARROW Cell isolation protocols usually include density

gradient centrifugation. With careful attention to detail the BMC system

gently and precisely processes bone marrow aspirate for the purest

concentration of these cells at the point of care. BMC is part of a

developmental effort to provide an effective therapy that is low risk. It


        recovers a large percentage of platelet rich plasma and other total
        nucleated cells in a treatment sample. It is a closed system with strong
        performance outcomes and outstanding product stability.




    ?   CELLGENIC PRP (Platelet Rich Plasma) is used to encourage healing and

reduce inflammation. As a concentrated source of autologous platelets, PRP

contains several growth factors and other cytokines that can stimulate the


        healing of soft tissues.




Global Stem Cells Group's future is looking bright as we look to bounce back
from the pandemic effect on our operations. We are uniquely positioned to reach
our revenue goals due to our global presence and network of independent
businesses. We stand positioned to give the world access to the full spectrum of
everything regenerative medicine can offer-- from being a source for products
themselves, to sourcing equipment, to treating patients. We are able to do this
because of our decade of experience in the field, and because of the world-class
leadership and organization of the Group.



Leaders in stem cell medicine trust the high quality of Global Stem Cells
Group's world-class stem cell therapies, and physicians all over the world have
come to value it as a trusted source for the newest ground-breaking research and
development in the field of regenerative Medicine.



                                       28

Patents and Proprietary Rights

We are committed to the protection of our intellectual property of proprietary products and process as well as trademarks and other methods described below.


Our business includes the development of proprietary cell therapy products as
well as revenue generating physician and patient based regenerative medicine /
cell therapy training services, cell collection and cell storage services, the
sale of cell collection and treatment kits for humans and animals, and the
operation of a cell therapy clinic.

On February 19, 2019, the U.S. Patent and Trademark Office ("USPTO") filed US service trademark, 5,682,488 which claims exclusive us of "ISCCA" as INTERNATIONAL SOCIETY FOR STEM CELL APPLICATION to Stem Cell Training Inc a Florida Corporation.

On April 30, 2019, the U.S. Patent and Trademark Office ("USPTO") granted US service trademark, 5,739,089 which claims exclusive us of "ISCCA" as INTERNATIONAL SOCIETY FOR STEM CELL APPLICATION to Stem Cell Training Inc a Florida Corporation.

We own proprietary protocols for the harvesting and isolation of Stem Cells Derived from the adipose tissue and Bone marrow.

We also own proprietary standard operating procedures for the manufacturing of allogeneic cellular therapy products derived from perinatal tissue.


None of these protocols or IP have been patented.. However, we rely on our own
trade secrets and proprietary know-how to protect our technology and maintain
our competitive position, since patent protection may not be available or
applicable to our technology.



Competition



We face competitors in many different segments of our business models. We face
intense competition from companies with much larger capital resources than us,
and, as a result, we could struggle to attract customers and gain market share.
Many of our existing or future competitors have greater financial resources and
greater brand name recognition than we do and, as a result, may be better
positioned to adapt to changes in the industry or the economy as a whole. We
will strive to advance our products and technology in each of these sectors
ahead of our competitors to gain market share. We also face intense competition
in attracting and retaining qualified employees. Our ability to continue to
compete effectively will depend upon our ability to attract new employees,
retain and motivate our existing employees and to compensate employees
competitively. We face significant competition in several aspects of our
business, and such competition might increase, particularly in the market for
regenerative therapies.



Our competitors may announce new products, services or enhancements that better
address changing industry standards on regenerative care. Any such increased
competition could cause pricing pressure, loss of business or decreased customer
purchases, any of which could adversely affect our business and operating
results.



We believe that we have competitive strengths and protection via our depth of
services and products that we offer in the regenerative medicine field,
including, but without limitation to, cell therapy products, isolation systems,
physician training, laboratory build outs, medical tourism, and more.

While there are particular or specific competitors in any one of these areas, no one is currently providing the full service one stop solution for such a complete range of offerings in this industry as we are.

Furthermore, we compete by becoming a resource, creating standards of practice, advancing the Stem Cell field in general, and by connecting associates and partners in many different aspects of the business.





Government Regulations



Although Stem Cell therapy is heavily regulated in the US by the Food and Drug
administrator, Global Stem Cells group does not focus its business portfolio in
US markets, to this end, we have suspended operations in the US. As such, we are
not constrained by FDA regulatory jurisdictions. We now operate exclusively in
countries where clear regulatory pathways to manufacturing and practice exist.



                                       29





Marketing



Global Stem Cell Group uses its vast network of professionals in the
regenerative and therapeutic industries to market and grow our business.
Training seminars held on location in more than a dozen international locations
have helped drive the attraction that is bringing new business to our group. The
ISCCA is our professional association and is a global network of medical
professionals that leverages these multinational relationships to build best
practices and further our mission. Our physician training services educate and
generate continued reoccurring demand for our solutions, services, and products.



The more we educate physicians about our products and services, the more
physician referrals we have received. It has been a difficult task to introduce
new methodologies to physicians with more traditional views, but word of mouth
has played a crucial role in the growth of our company and our reputation in the
industry. We believe our website will further expand our growth as new
physicians have an easy to understand synopses of our how our products and
services may assist with and benefit their patients. We believe that as our
network of physicians widens we will experience significant growth from repeat
business from existing clients and with new business from patient referrals.



Numismatics Operations

Meso Numismatics, Inc., has established a growing numismatics operation Meso Numismatics focuses on the Central American Caribbean region with a concentration of products surrounding Mesoamerica (Mexico to Panama).


Having locations in Costa Rica and Florida for the purposes of conveniently
shipping products, the Company has the ability to export its inventory of coins,
paper currency, bullion and medals from Costa Rica, to be sold in the U.S. and
around the world. Likewise, the Company also imports such products back to Costa
Rica, to be sold throughout the local markets.



The Company adheres to strict processes related to acquisition and sale of its
products. It begins by selecting the best inventory, be it a rare coin from
Latin America, or a banknote with an error from the United States. All inventory
is carefully screened by management, then sent to be graded by the proper
grading authority. For all coins, medals and bullion, the Company's inventory is
sent to the Numismatic Guaranty Company for authentication and grading. For all
banknotes, the Company utilizes the services of Paper Money Guaranty, LLC for
authentication and grading, both Florida-based companies. Once graded, the
inventory is sent to the Company's Florida-based location prior to being sent to
one of the Company's many customers around the world.



We maintain an online store with eBay (www.mesocoins.com) and participate in
live auctions with major companies such as Heritage Auctions, Stacks Bowers
Auctions, Lyn Knight Auctions and Sedwick Coins for the sale of its coins, paper
currency, bullion and medals. The Company also launched a new application
technology available on the Google Play Store, as well as the Apple App Store.
The Application is a banknote scanner which instantly identifies key
characteristics of a banknote. This includes the catalog reference number of the
note, the value, which entity it was issued by, the country of origin and the
printer that printed the note. A picture of each note from our database of more
than 61,000 banknotes from a combined 750 countries and regions will also be
included with the information. For the numismatic industry in particular, this
application eliminates the need for reference books, as well as the hours of
time it takes to reference all the information about banknotes. With a simple
snap of a picture, information is provided to the end-user almost
instantaneously.



Meso expects to continue to acquire rare inventory at market rates, from
throughout the Meso Region (including Central America and the Caribbean). The
inventory is then sent for authentication and grading, followed by said items
being sold throughout Meso's sales outlets. This includes an eBay store with up
to, but not limited to, $50,000 in items for sale at any one time. For some of
the Company's rarer inventory, items are sent to major auction houses around the
world for sale.



As of December 31, 2021, the Company is working on an inventory tracking system
by serial number. Until such time the inventory costs cannot be properly
confirmed, therefore any inventory balances are expensed during each reporting
period.



                                       30





License Agreements



Coins / Medals

The Company's inventory is comprised of roughly 50% coins / medals and 50% paper money. The Company has a meticulous process for the acquisition and sales process for each coin item. The Company specializes in coins from the Meso region, but also acquires coins and medals from elsewhere around the world.





The process starts by visiting local shops and establishments throughout the
Meso region to gather information about the coins that Company's management is
considering for acquisition. Once an item has been selected, it is paid for,
then packaged and sent from Meso's Costa Rica location to the Company's Florida
location. From there, the merchandise is once again examined, then sent to NGC
(the Numismatic Guaranty Company) for grading and authentication. After
approximately three weeks, the items are sent back to Meso's Florida location
for storage, safekeeping and subsequent distribution to its respective
destinations.



Management carefully evaluates the grades assigned to each piece of merchandise
and then decides which items will be sold through its eBay store, which items
will be sold at live auction and which items will be traded for other items.
Some pieces are also sent back to Costa Rica for trading, some are sold on eBay
and some go to auction powerhouses around the globe.



Meso also acquires ungraded coins / medals from eBay, as well as at specialty
shops throughout the Meso region and during certain U.S. shows. Those items are
taken through the same aforementioned process.



Paper Money

As indicated above, paper money makes up approximately 50% of Meso's inventory. The process of acquiring paper money almost mirrors that of coins / medals.

Meso's management often visits local banks and central banks throughout the Meso
region. Management selects banknotes within bundles, aiming to acquire rare and
exceptional notes. This includes RADARS (the same serial number back-and-forth),
errors and uncirculated rarities.



The note is then sent from Costa Rica to Florida for grading and authentication.
For this service, the Company utilizes the Paper Money Guaranty, which is
expected to examine the note in great detail, then offers a grade for its
condition. The note is encased, then sent back to Meso's Florida location for
distribution to its final destination. Similarly to coins, management inspects
each note, then decides whether it will be sold on eBay, at a specialty auction,
or traded for other merchandise in the Meso Region.



Similar to coins, Meso also purchases ungraded notes on eBay or at other stores,
has them graded through the same process, then decides where to sell it at

the
end.



Industry Overview



Numismatics itself is the study or collecting of currency, including but not
limited to paper money, coins, medals, tokens and other objects. Numismatics is
often associated with stamp collecting, philately, and is equally as popular
when it comes to hobbies around the world.



The numismatic industry is a multi-billion-dollar market that continues to grow
year-over-year. Estimates provided by PNG (The Professional Numismatists Guild)
placed the U.S. rare coin market at between $3.4 and $4 billion in 2018.



At the forefront of the numismatic industry is NGC (The Numismatics Guaranty
Company) and PMG (The Paper Money Guaranty). These two organizations, with
locations around the world, are responsible for the majority of authenticating
and grading various forms of currency. Since its inception in 1987, NGC has
graded more than 42 million coins, with 61% representing the US, 16%
representing Asia, $13% representing Europe, and, a combined 8% representing
Africa, South America and Australia.



                                       31





Growth Strategy



According to an article published in a May 2017 edition of The Economist, the
global numismatic market has a value between $5 Billion and $8 Billion per year.
It has been noted that out of all the global numismatic sales around the world,
the United States is responsible for roughly 85% of the market, further depicted
in the chart below. We believe we can capture market share in the U.S. market
and we believe we are well positioned to take advantage of, As indicated by the
following chart, the Company has the opportunity for growth within the U.S. and
the Latin American region as well. The Company has the opportunity for growth
within the Latin American region as well. The Company also expects to perform
outreach and educate Latin America and Australia about the value of numismatics.



Many Latin American countries postal services are difficult to navigate due to
political unrest and corruption. We believe we have an advantage by having boots
on the ground in Costa Rica, and associates throughout all of Latin America,
which affords us the opportunity to procure almost any type of item and safely
have it graded and then sold.



Successful importation and exportation of merchandise between Central America
and the United States is crucial for the Company. Being able to acquire
inventory at reduced costs, then selling the items for healthy profits, once
graded, continues to be the key to growth.



The Company anticipates organic growth as well growth through acquisitions, as
the right opportunities present themselves. The Company has and will continue to
reinvest capital in new inventory, further supporting its long-term goal of
becoming a recognized, global numismatic brand. Possible future acquisitions
include websites / social media pages, in addition to physical numismatic
businesses that could become available. These acquisitions could be solely of a
company's inventory, or their physical location and assets as well.



Competitive Strengths



Technology

To our knowledge, Meso Numismatics has the only banknote scanner on the market. The technology, mostly utilized by numismatists, quickly assesses all the information about a banknote and almost instantly displays the information, along with a replica banknote from the database.





The Meso App, available on the Google Play Store and the Apple App Store, is
expected to eventually be transitioned into a platform to buy, sell, and trade
banknotes. Monetization is expected come from advertisers displaying banner ads,
as well as transactional fees from the sales of items. The Company also has the
ability, although it does not do so yet, to charge the user for general use

of
the App.



Location



Meso Numismatics has office locations in San Jose, Costa Rica and Boca Raton,
Florida. Having dual locations, especially in these two areas in particular, is
extremely advantageous to the Company.



The Costa Rican location of Meso is pivotal for the Company. Management in this
location is able to obtain some items, below-market prices due to relationships
made within the industry. While a US collector must pay for an item (usually
with a premium) plus shipping and handling, having management on the ground
allows the Company to acquire items without the extra costs. Management also has
relationships with dealers throughout the region and trades / exchanges
merchandise for better items. The majority of the Company's inventory originates
in Costa Rica, then is shipped to Florida for grading and authentication.



The Boca Raton location of Meso is almost as pivotal as the Costa Rican
location, as the leading grader and authenticator of merchandise (PMG and NGC)
also has locations in Florida. Merchandise is sent from Costa Rica to Boca
Raton. Once inventoried, merchandise is sent to PMG or NGC for grading and
authenticating. Once complete, the inventory is returned to the Boca Raton
location where it is safely housed and distributed to its final location. Having
this location allows the Company to ship items globally at significantly lower
rates than shipping from Costa Rica.



                                       32





Strategic Partnerships



Meso has strategically partnered with Softon Digital ("Softon") of Costa Rica,
in addition to the above relationships with PMG and NGC. Softon assisted in the
development and creation of the Meso App and it is expected that Softon will
continue to help the Company evolve the technological portion of the business,
with their team of programmers and engineers.



Competition




In the coins and other collectibles business, we will compete with a number of
comparably sized and smaller firms, as well as a number of larger firms
throughout the United States. Our primary competitors are American Numismatic
Rarities, a comparably-sized coin auctioneer. Many of our competitors have the
ability to attract customers as a result of their reputation and the quality
collectibles they obtain through their industry connections. Additionally, other
reputable companies that sell rare coins and other collectibles may decide to
enter our markets to compete with us. These companies have greater name
recognition and have greater financial and marketing resources than we do. If
these auction companies are successful in entering the specialized market for
premium collectibles in which we participate or if dealers and sellers
participate less in our auctions, we may attract fewer buyers and our revenue
could decrease.



Results of Operations

Results of Operations for the Three Months Ended March 31, 2022 and 2021.





Below is a summary of the results of operations for the three months ended March
31, 2022 and 2021.



                                                      For the Three Months Ended March 31,
                                                                                                %
                                               2022            2021          $ Change        Change
Revenue                                    $    310,078     $    4,443     $    305,635         6,879 %
Cost of revenue                                 203,593         14,790          188,803         1,277 %
Gross profit                                    106,485        (10,347 )        116,832         1,129 %

Operating expenses
Advertising and marketing                        54,614            237           54,377        22,944 %
Professional fees                               395,739        113,787          281,952           248 %
Officer compensation                             22,500         15,000            7,500            50 %
Depreciation and amortization expense            26,977            200     

     26,777        13,388 %
Investor relations                               47,250          2,898           44,352         1,530 %
General and administrative                      101,918         10,610           91,308           861 %
Total operating expenses                        648,998        142,732          506,266           355 %

Other income (expense)
Interest expense                             (1,140,529 )     (319,228 )       (821,301 )         257 %

Derivative financial instruments                  6,079              -     

      6,079           100 %
Net loss                                   $ (1,676,963 )   $ (472,307 )   $ (1,204,656 )         255 %




                                       33





Revenue




Revenue increased by 6,879% in the amount of $305,635 for the three months ended
March 31, 2022, compared to the same period in 2021. The key reason for the
increase in revenue was a result of the acquisition of Global Stem Cells Group,
Inc. on August 18, 2021. Revenue from viable cell therapy and immune support
related products along with physician training was $298,748 and an increase in
sale of coins, metals and paper money of $6,887 for the three months ended March
31, 2022, compared to the same period in 2021.

Listed below are the revenues, cost of revenues and gross profits by Company for the three months ended March 31, 2022:





                                        For the Three Months Ended
                                              March 31, 2022
                   Global Stem          Meso
                   Cells Group       Numismatics            Total
Revenue           $     298,749     $      11,329       $      310,078
Cost of revenue         192,484            11,109              203,593
Gross profit      $     106,265     $         220       $      106,485
Gross profit %            35.57 %            1.95 %              34.34 %




Operating expenses



Operating expenses increased by 355% in the amount of $506,266 for the three
months ended March 31, 2022, compared to the same period in 2021. Listed below
are the major changes to operating expenses:

Professional fees increased by $281,952 for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to $55,800 in consulting and $193,000 in audit and accounting expenses.





Officer compensation increased by $7,500 for the three months ended March 31,
2022, compared to the same period in 2021, primarily due to a monthly based on
annual rate of $90k starting January 1, 2022

General and administrative expense increase by $91,308 for the three months ended March 31, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.





Other expense



Other expense increased by $815,222 for the three months ended March 31, 2022,
compared to the same period in 2021, primarily as a result of the increase in
amortization of discounts and interest on promissory notes.



Net Loss

We recorded a net loss of $1,676,964 for the three months ended March 31, 2022, as compared with a net loss of $472,307 for the same in 2021.

Liquidity and Capital Resources

Since inception, the Company has financed its operations through private placements and convertible notes. The following is a summary of the cash and cash equivalents as of March 31, 2022 and December 31, 2021.





                             March 31,       December 31,                        %
                               2022              2021           $ Change       Change
Cash and cash equivalents   $ 2,461,023     $    2,978,525     $ (517,502 )        -17 %




                                       34

© Edgar Online, source Glimpses